Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

- Blood pressure reduction achieved at 8 am versus placebo: - 25 / - 13 mm Hg (systolic / diastolic, p<0.0001 / p=0.0035)
- Blood pressure reduction dependent on vaccine dose and induced antiangiotensin II antibody levels
- Detailed results presented today at the Seventeenth European Meeting on Hypertension in Milan, Italy

SCHLIEREN (Zurich), Switzerland and MILAN, Italy, June 17, 2007 - Cytos Biotechnology AG (SWX:CYTN) presented today new clinical data on its hypertension vaccine CYT006-AngQb at the Seventeenth European Meeting on Hypertension in Milan, Italy. The vaccine candidate was tested in a placebocontrolled, double-blind phase IIa clinical trial in 72 patients with mild to moderate hypertension.

On January 26, 2007, Cytos Biotechnology reported top-line data from this study, which showed that the 300 ?g dose of the vaccine was safe, very well tolerated and efficacious in lowering day-time ambulatory blood pressure. The new data presented today show a particularly strong efficacy of the vaccine in early morning hours, a critical time period when serious cardiovascular events frequently occur. The graph below shows the mean ambulatory blood pressure during the 24-hour measurement period 14 weeks after the first injection of the vaccine or of placebo. The early morning rise of blood pressure starting at 5 am was significantly suppressed by the vaccine, leading at 8 am to a change from baseline of the blood pressure of - 25 / - 13 mm Hg compared to placebo (SBP / DBP, p<0.0001 / p=0.0035).


*SEE ATTACHMENT FOR FIGURE*

The strong suppression of the early morning rise of blood pressure was associated with an exceptionally low increase in plasma renin concentration (PRC) from a mean renin concentration of 5.1 pg/ml at baseline to 6.3 pg/ml at week 14 (p=0.02). Inhibition of the renin-angiotensin system by small molecule drugs is known to induce a reactive rise of the plasma renin concentrati
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:5/15/2008)...5 /- Cytopia Limited,(ASX: ...oming oral,presentation on CYT997 at the 2008 Annu...ology (ASCO) will be accessible to the public via ... Thursday 15 May (US EDT)., The oral presentation...cytotoxic and vascular disrupting agent, in patien...
(Date:5/15/2008)...- Sanofi-aventis,(EURONEXT:...from the,landmark ATHENA study showed Multaq(R) (d... of patients with atrial fibrillation or atrial fl...alizations or death from any,cause by a statistica...udy,primary endpoint. The ATHENA results will be p...
(Date:5/15/2008)... -- CenterWatch, a publishing and,information serv...ical,trials, finds that investigative sites are re...ure) systems. More than 75% of respondents to a re...en trained on three or more,EDC systems. In additi...,their EDC training had improved., State of the C...
(Date:5/15/2008)...ice Plan Positions Blue Cross Blue Shield of ...eport from HealthLeaders-In...- HealthLeaders-InterStudy, the,leading provider o...s the,economy continues to stagnate in Michigan, B... equipped of all of its competitors to weather the...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Trial to Test Gene Therapy for Angina in Women 489 1Trial to Test Gene Therapy for Angina in Women 489 2Trial to Test Gene Therapy for Angina in Women 489 3Researchers develop simple method to create natural drug products 248 1Researchers develop simple method to create natural drug products 248 2EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron LLC to Ceradyne Inc for 2469 Million 485 1EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron LLC to Ceradyne Inc for 2469 Million 485 2HealthInsuranceFinders com Launches Video Contest for Young Directors 481 1HealthInsuranceFinders com Launches Video Contest for Young Directors 481 2
(Date:5/16/2008)...Frail Seniors and People With,Disabilities, OAKLA...sands of,homecare workers across the state are out...s to hours of service, wages and benefits,which w...rkers and the,people they serve deeper into povert...eniors and people with disabilities from Schwarzen...
(Date:5/16/2008)...ational HIV Vaccine Awareness Day, May,18, WASHIN... years into the,AIDS epidemic, someone is newly in...nday, May 18, HIV Vaccine Awareness Day, AIDS Acti...Institute of Allergy and Infectious,Disease (NIAID... everyone,to help end the AIDS epidemic by partici...
(Date:5/16/2008)...ntsworth plc (LSE: HNT), "the Group",a leading in...ications,group headquartered in London, released i...roup,s performance in the first quarter 2008 (the ...ollows below., 15 May 2008, ...rim Management Statement, Record net n...
(Date:5/16/2008)...More in 2007, WASHINGTON, May 16 /PRNewswire-USNe...ancer deaths, the National Cancer Institute (NCI) ...n lung cancer research in 2007,according to updat... today., The two other federal agencies with sign...sease Control and Prevention (CDC) and the,Departm...
Breaking Medicine News(10 mins):Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Lung Cancer Still Lowest in Federal Funding 2
...al new cancer treatment might cause a cancer revol...eatment targets tumors with radioactive microspher...therapy is most often used for bowel cancer patien... but is expected to be extended to other cancers. ...
...ho are bogged down with fertility problems can now...n conscientiously engaged in the study of a protei...e fertilized egg in the uterus. The team studied ...e menstrual cycles of 12 women with previous histo...
...ng to the recent research conducted by Dr. Michael...that death rates due to lung cancer among non smok...ver smoked had higher lung cancer death rates than... Americans. Lung cancer is by far the biggest canc...
...a's Health and Human Services Minister, Lara Giddi...cedures in the department. // This was part of a n...ceston this morning to 200 of the health departmen...ers. The main aim is to reduce the number of appr...
Other Medicine News:Health News:A Revolutionary New Treatment For Cancer Available In Australia 2
...d human blood cells provides a simple, cost effect...ation of urine prior to microscopic analysis in co...tion of urine sediment is a moderately complex tes...and quantitative values are provided for standardi...
...enience for urinalysis quality control one bottle...product for dipstick, hCG, and microscopics qualit...nine and microalbumin. Values are provided for mic... qualitative results for hCG are also included. Di...
... is ideal for most life science applications, espe...tented* PathCheck sensor technology senses the dep...alizes the absorbance value to a 1-cm pathlength. ... obtained in a conventional spectrophotometer. ,...
The Clearblue Easy Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the 2 best
Medicine Products: